3. INTRODUCTION
The therapeutic effectiveness of a drug
depends upon the ability of dosage
form to deliver the medicament to its
site of action at a rate and attribute of a
dosage form.
API in
dosage form
API in free
form
API in
systemic
circulation
Therapeutic
action
7. INTRODUCTION
However, for reasons of stability and
convenience, most drug are
administered orally. In such case the
dose available to the patient, called as
bioavailable dose.
Bioavailable fraction:-
Bioavailable dose
=
Administered dose
8. OBJECTIVE
In R&D of suitable dosage form.
Determination of influence of excipient,
patient related factors and drug
interaction on the efficiency of absorption.
Development of new formulation of
existing drug.
QC of dosage form.
Comparison of BA of a drug substance
from different dosage forms or from the
same dosage form produce by different
manufacture.
9. CONSIDERATION IN BIOAILABILITY STUDY
DESIGN
Absolute vs. relative
Absolute bioavailability (F):-
When the systemic BA of a drug
administer orally is determine to its i.v
administration, it is called as absolute BA.
o Importance:-
To characterize drug’s inherent
absorption properties from the i.v site.
10. CONSIDERATION IN BIOAILABILITY STUDY
DESIGN
Relative bioavailability (Fr):-
When the systemic availability of
a drug after oral administration is
compare with that of an oral standard of
the same drug it is refer to as
comparative or relative bioavailability.
o Importance:-
Used to characterize absorption of
drug from its formulation.
11. CONSIDERATION IN BIOAILABILITY STUDY
DESIGN
Single dose vs. Multiple Dose
studies.
The dose to be administered
for a bioavailability study is determine
by preliminary clinical experiment.
12. CONSIDERATION IN BIOAILABILITY STUDY
DESIGN
Advantages
It is very conman
study
Less exposure to
drug
Less tedious
Disadvantages
Difficult to produce
steady state
characteristics of drugs
Long sampling period
are necessary.
Single dose study
13. CONSIDERATION IN BIOAILABILITY STUDY
DESIGN
Advantages
More accurate
Easy to predict peak
characteristics
Require collection of fewer
blood sample
Can be ethically performed in
patient
Small inter-subject variability is
observed.
Multiple dose study
14. CONSIDERATION IN BIOAILABILITY STUDY
DESIGN
Disadvantages
Require more time.
Tedious.
Poor compliance by subject
Greater exposure of subject to
the test drug.
15. CONSIDERATION IN BIOAILABILITY STUDY
Design
Human volunteers-Healthy Subject
vs. Patient
Ideally, the bioavailability study
should be carried out in patients for
whom the drug is intended to be used.
16. CONSIDERATION IN BIOAILABILITY STUDY
Design
Patients
Will be benefited
from the study
Reflects better
the therapeutic
efficacy of
drug.
Drug absorption
patterns can be
evaluated
Avoid the ethical
quandary of
administering
drug to healthy
subject.
18. MEASUREMENT OF BOAVAILABILITY
Pharmacokinetic method:-
These method are based on
the assumption that the
pharmacokinetic profile reflects the
therapeutic effectiveness of a drug.
Thus, these are indirect methods
19. MEASUREMENT OF BOAVAILABILITY
Plsma level time studies:-
• Most common type of human bioavailability
studies.
• Based on the assumption that there is a
direct relationship between the
concentration of drug in blood or plasma
and the concentration of drug at the site of
action.
• Following the administration of a single
dose of a medication, blood samples are
drawn at specific time intervals and
20. MEASUREMENT OF BOAVAILABILITY
Following the administration of a single
dose of a medication, blood samples are
drawn at specific time intervals and
analyzed for drug content.
A profile is constructed showing the
concentration of drug in blood at the
specific times the samples were taken.
Bioavailability is generally assessed by
the determination of following three
parameters.
21. MEASUREMENT OF BOAVAILABILITY
Two dosage form having same plasma
level time profile should result in identical
therapeutic activity.
Plot of concentration vs. time of sample
collection to obtained a plasma level
time profile
25. MEASUREMENT OF BOAVAILABILITY
Cmax: (Peak plasma drug
concentration)
Maximum concentration of the drug
obtained after the administration of single
dose of the drug.
Expressed in terms of μg/ml or mg/ml.
Tmax: (Time of peak plasma conc.)
Time required to achieve peak
concentration of the drug after
administration.
Gives indication of the rate of absorption.
Expressed in terms of hours or minutes.
26. MEASUREMENT OF BOAVAILABILITY
AUC: -
Is the measurement of the extent of the
drug bioavailability
It is the area under the drug plasma
level-time curve from t =0 & t = ∞, and
is equal to the amount of unchanged
drug reaching the general circulation
divided by the clearance.
27. MEASUREMENT OF BOAVAILABILITY
The extent of bioavailability can be
determined by the following equations:
For single dose study
For multiple dose study:
28. MEASUREMENT OF BOAVAILABILITY
Urinary Excretion Studies:
Urinary excretion of unchanged drug is directly
proportional to plasma concentration of drug.
Thus, even if a drug is excreted to some extent
(at least 10 to 20%) in the urine, bioavailability
can be determined.
e.g.: Thiazide diuretics, Sulphonamides.
• Method is useful when there is lack of sufficiently
sensitive analytical technique to measure drug
concentration.
Noninvasive method, so better patient
compliance.
29. MEASUREMENT OF BOAVAILABILITY
Three Important Parameters in urine
excretion data for single dose study:
(dxu/dt)max (tu)max
Xu∞
31. MEASUREMENT OF BOAVAILABILITY
(dxu/dt)max :(Maximum urinary excretion
rate)
• Its value increases as rate and/or extent
of absorption increases.
• Obtained from peak of plot between rate
of excretion versus midpoint time of
urine collection period.
(tu) max:
• Time for maximum excretion rate
32. MEASUREMENT OF BOAVAILABILITY
• Its value decreases as absorption rate
increases.
• Analogues of tmax of plasma level data.
Xu
∞:Cumulative amount of drug
excreted in urine
• Related to AUC of plasma level data.
• It increases as the extent of
absorption increases.
33. MEASUREMENT OF BOAVAILABILITY
The extent of bioavailability is
calculated from equation :
For single dose study:
For multiple dose study:
34. MEASUREMENT OF BOAVAILABILITY
Acute Pharmacologic Response
Method:
• When bioavailability measurement by
pharmacokinetic method is difficult, an
acute pharmacologic effect such as
effect on pupil diameter, EEG & ECG
readings related to time course of
drug.
• Bioavailability can then be determined
by construction of pharmacological
effect- time curve as well as dose
response graphs.
35. MEASUREMENT OF BOAVAILABILITY
Disadvantage:
• It tends to be more variable.
• Observed response may be due to an
active metabolite whose concentration
is not proportional to concentration of
parent drug.
36. MEASUREMENT OF BOAVAILABILITY
Therapeutic Response Method:
• This method based on observing the
clinical response to a drug formulation
given to patient suffering from disease.
37. MEASUREMENT OF BOAVAILABILITY
Drawbacks: The major drawbacks of
this method is that quantitation of
observed response is too improper to
allow for reasonable assessment of
relative bioavailability between two
dosage forms of the same drug.
E.g.: Anti-inflammatory
drugs.
Many patients receive more than one
drug
38. MEASUREMENT OF BOAVAILABILITY
Drug dissolution studies may under
certain conditions give an indication of
drug bioavailability.
Dissolution studies are often
performed in several test formulations
of the same drug.
39. MEASUREMENT OF BOAVAILABILITY
The test formulation that demonstrates
the most rapid rate of drug
bioavailability in-vitro will generally
have the most rapid rate of drug
bioavailability in-vivo.
The FDA may also use the other in-
vitro approaches for establishing
bioequivalence.
Ex: Cholestyramine resin.
40. REFRENCES
• Brahmankar .D.M , Sunil Jaiswal,
“Biopharmaceutics and
Pharmacokinetics-A Treatise”, Second
edition, page no. 236-337.
• V Venkateshwarlu,
“ Biopharmaceutics &
pharmacokinetics’’
page no. 403-416.